Syndax Pharmaceuticals Inc’s recent filing unveils that its Chief Executive Officer Metzger Michael A unloaded Company’s shares for reported $2.58 million on Sep 08 ’25. In the deal valued at $16.41 per share,157,307 shares were sold. As a result of this transaction, Metzger Michael A now holds 298,661 shares worth roughly $6.11 million.
Then, MICHAEL METZGER bought 157,307 shares, generating $2,680,511 in total proceeds.
Before that, Podlesak Dennis sold 19,200 shares. Syndax Pharmaceuticals Inc shares valued at $304,170 were divested by the Director at a price of $15.84 per share. As a result of the transaction, Podlesak Dennis now holds 191,763 shares, worth roughly $3.93 million.
BTIG Research maintained its rating on August 05, 2025. It rated SNDX as “a Buy”.
Price Performance Review of SNDX
On Tuesday, Syndax Pharmaceuticals Inc [NASDAQ:SNDX] saw its stock fall -1.21% to $20.47. Over the last five days, the stock has gained 0.64%. Syndax Pharmaceuticals Inc shares have risen nearly 56.14% since the year began. Nevertheless, the stocks have fallen -2.57% over the past one year.
How much short interest is there in Syndax Pharmaceuticals Inc?
A steep rise in short interest was recorded in Syndax Pharmaceuticals Inc stocks on 2025-12-31, dropping by -2.65 million shares to a total of 22.57 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-28 was 25.22 million shares. There was a decline of -11.75%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on July 10, 2025 when Goldman began covering the stock and recommended ‘”a Buy”‘ rating along with a $18 price target.
